<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1707245590
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2000
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        MICARDIS 40 MG TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TELMISARTAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        49.60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="BOEHRINGER INGELHEIM" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            BOEHRINGER INGELHEIM
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            BOEHRINGER INGELHEIM
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09CA07
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Micardis belongs to a class of medicines known as angiotensin II receptor blockers. Angiotensin II is a substance produced in your body which causes your blood vessels to narrow, thus increasing your blood pressure. Micardis blocks the effect of angiotensin II so that the blood vessels relax, and your blood pressure is lowered.</p><p>Micardis is used to treat essential hypertension (high blood pressure) in adults. &lsquo;Essential&rsquo; means that the high blood pressure is not caused by any other condition.</p><p>High blood pressure, if not treated, can damage blood vessels in several organs, which could lead sometimes to heart attack, heart or kidney failure, stroke, or blindness. There are usually no symptoms of high blood pressure before damage occurs. Thus it is important to regularly measure blood pressure to verify if it is within the normal range.</p><p>Micardis is also used to reduce cardiovascular events (i.e. heart attack or stroke) in adults who are at risk because they have a reduced or blocked blood supply to the heart or legs, or have had a stroke or have high risk diabetes. Your doctor can tell you if you are at high risk for such events.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Micardis</p><p>&bull; if you are allergic to telmisartan or any of the other ingredients of this medicine (listed in section 6).</p><p>&bull; if you are more than 3 months pregnant. (It is also better to avoid Micardis in early pregnancy &ndash; see pregnancy section.)</p><p>&bull; if you have severe liver problems such as cholestasis or biliary obstruction (problems with drainage of the bile from the liver and gall bladder) or any other severe liver disease.</p><p>&bull; if you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren.</p><p>If any of the above applies to you, tell your doctor or pharmacist before taking Micardis.</p><p>Warnings and precautions</p><p>Talk to your doctor before taking Micardis if you are suffering or have ever suffered from any of the following conditions or illnesses:</p><p>&bull; Kidney disease or kidney transplant.</p><p>&bull; Renal artery stenosis (narrowing of the blood vessels to one or both kidneys).</p><p>&bull; Liver disease.</p><p>&bull; Heart trouble.</p><p>&bull; Raised aldosterone levels (water and salt retention in the body along with imbalance of various blood minerals).</p><p>&bull; Low blood pressure (hypotension), likely to occur if you are dehydrated (excessive loss of body water) or have salt deficiency due to e.g. diuretic therapy (&#39;water tablets&#39;), low-salt diet, diarrhoea, or vomiting.</p><p>&bull; Elevated potassium levels in your blood.</p><p>&bull; Diabetes.</p><p>Talk to your doctor before taking Micardis:</p><p>&bull; if you are taking any of the following medicines used to treat high blood pressure: - an ACE-inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes-related kidney problems. - aliskiren. Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your blood at regular intervals. See also information under the heading &ldquo;Do not take Micardis&rdquo;.</p><p>&bull; if you are taking digoxin.</p><p>Talk to your doctor if you experience abdominal pain, nausea, vomiting or diarrhoea after taking Micardis. Your doctor will decide on further treatment. Do not stop taking Micardis on your own.</p><p>You must tell your doctor if you think you are (or might become) pregnant. Micardis is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section).</p><p>In case of surgery or anaesthesia, you should tell your doctor that you are taking Micardis.</p><p>Micardis may be less effective in lowering the blood pressure in black patients.</p><p>Children and adolescents</p><p>The use of Micardis in children and adolescents up to the age of 18 years is not recommended.</p><p>Other medicines and Micardis</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Your doctor may need to change the dose of these other medications or take other precautions. In some cases you may have to stop taking one of the medicines. This applies especially to the medicines listed below taken at the same time with Micardis:</p><p>&bull; Lithium containing medicines to treat some types of depression.</p><p>&bull; Medicines that may increase blood potassium levels such as salt substitutes containing potassium, potassium-sparing diuretics (certain &#39;water tablets&#39;), ACE inhibitors, angiotensin II receptor blockers, NSAIDs (non steroidal anti-inflammatory medicines, e.g. aspirin or ibuprofen), heparin, immunosuppressives (e.g. cyclosporin or tacrolimus), and the antibiotic trimethoprim.</p><p>&bull; Diuretics (&#39;water tablets&#39;), especially if taken in high doses together with Micardis, may lead to excessive loss of body water and low blood pressure (hypotension).</p><p>&bull; If you are taking an ACE-inhibitor or aliskiren (see also information under the headings &ldquo;Do 61 not take Micardis&rdquo; and &ldquo;Warnings and precautions&rdquo;).</p><p>&bull; Digoxin.</p><p>The effect of Micardis may be reduced when you take NSAIDs (non steroidal anti-inflammatory medicines, e.g. aspirin or ibuprofen) or corticosteroids.</p><p>Micardis may increase the blood pressure lowering effect of other medicines used to treat high blood pressure or of medicines with blood pressure lowering potential (e.g. baclofen, amifostine). Furthermore, low blood pressure may be aggravated by alcohol, barbiturates, narcotics or antidepressants. You may notice this as dizziness when standing up. You should consult with your doctor if you need to adjust the dose of your other medicine while taking Micardis.</p><p>Pregnancy and breast-feeding</p><p>Pregnancy</p><p>You must tell your doctor if you think you are (or might become) pregnant. Your doctor will normally advise you to stop taking Micardis before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Micardis. Micardis is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.</p><p>Breast-feeding</p><p>Tell your doctor if you are breast-feeding or about to start breast-feeding. Micardis is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.</p><p>Driving and using machines</p><p>Some people may experience side effects such as fainting or a feeling of spinning (vertigo) when taking Micardis. If you experience these side effects, do not drive or operate machinery.</p><p>Micardis contains sorbitol.</p><p>Micardis 40 mg contains 168.64 mg sorbitol in each tablet.</p><p>Micardis 80 mg contains 337.28 mg sorbitol in each tablet. Sorbitol is a source of fructose. If your doctor has told you that you have an intolerance to some sugars or if you have been diagnosed with hereditary fructose intolerance (HFI), a rare genetic disorder in which a person cannot break down fructose, talk to your doctor before you take or receive this medicine.</p><p>Micardis contains sodium</p><p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium- free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>The recommended dose is one tablet a day. Try to take the tablet at the same time each day.</p><p>You can take Micardis with or without food. The tablets should be swallowed whole with some water or other non-alcoholic drink. It is important that you take Micardis every day until your doctor tells you otherwise. If you have the impression that the effect of Micardis is too strong or too weak, talk to your doctor or pharmacist.</p><p>&nbsp;</p><p>For treatment of high blood pressure, the usual dose of Micardis for most patients is one 40 mg tablet once a day to control blood pressure over the 24 hour period. However, sometimes your doctor may recommend a lower dose of 20 mg or a higher dose of 80 mg. Alternatively, Micardis may be used in combination with diuretics (&#39;water tablets&#39;) such as hydrochlorothiazide which has been shown to have 62 an additive blood pressure lowering effect with Micardis.</p><p>&nbsp;</p><p>For reduction of cardiovascular events, the usual dose of Micardis is one 80 mg tablet once a day. At the beginning of the preventive therapy with Micardis 80 mg, blood pressure should be frequently monitored.</p><p>If your liver is not working properly, the usual dose should not exceed 40 mg once daily.</p><p>&nbsp;</p><p>If you take more Micardis than you should</p><p>If you accidentally take too many tablets, contact your doctor, pharmacist, or your nearest hospital emergency department immediately.</p><p>If you forget to take Micardis</p><p>If you forget to take a dose, do not worry. Take it as soon as you remember then carry on as before. If you do not take your tablet on one day, take your normal dose on the next day. Do not take a double dose to make up for forgotten individual doses.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Some side effects can be serious and need immediate medical attention</p><p>You should see your doctor immediately if you experience any of the following symptoms:</p><p>Sepsis* (often called &quot;blood poisoning&quot;, is a severe infection with whole-body inflammatory response), rapid swelling of the skin and mucosa (angioedema); these side effects are rare (may affect up to 1 in 1,000 people) but are extremely serious and patients should stop taking the medicine and see their doctor immediately. If these effects are not treated they could be fatal.</p><p>Possible side effects of Micardis</p><p><u>Common side effects</u> (may affect up to 1 in 10 people):</p><p>Low blood pressure (hypotension) in users treated for reduction of cardiovascular events.</p><p><u>Uncommon side effects</u> (may affect up to 1 in 100 people):</p><p>Urinary tract infections, upper respiratory tract infections (e.g. sore throat, inflamed sinuses, common cold), deficiency in red blood cells (anaemia), high potassium levels, difficulty falling asleep, feeling sad (depression), fainting (syncope), feeling of spinning (vertigo), slow heart rate (bradycardia), low blood pressure (hypotension) in users treated for high blood pressure, dizziness on standing up (orthostatic hypotension), shortness of breath, cough, abdominal pain, diarrhoea, pain in the belly, bloating, vomiting, itching, increased sweating, drug rash, back pain, muscle cramps, muscle pain (myalgia), kidney impairment including acute kidney failure, pain in the chest, feeling of weakness, and increased level of creatinine in the blood.</p><p><u>Rare side effects</u> (may affect up to 1 in 1,000 people):</p><p>Sepsis* (often called &quot;blood poisoning&quot;, is a severe infection with whole-body inflammatory response which can lead to death), increase in certain white blood cells (eosinophilia),low platelet count (thrombocytopenia), severe allergic reaction (anaphylactic reaction), allergic reaction (e.g. rash, itching, difficulty breathing, wheezing, swelling of the face or low blood pressure), low blood sugar levels (in diabetic patients), feeling anxious, somnolence, impaired vision, fast heart beat (tachycardia), dry mouth, discomfort in the belly, taste disturbance (dysgeusia), abnormal liver function (Japanese patients are more likely to experience this side effect), rapid swelling of the skin and mucosa which can also lead to death (angioedema including fatal outcome), eczema (a skin disorder), redness of skin, hives (urticaria), severe drug rash, joint pain (arthralgia), pain in extremity, tendon pain, flu-like-illness, decreased haemoglobin (a blood protein), increased levels of uric acid, increased hepatic enzymes or creatine phosphokinase in the blood, low levels of sodium.</p><p>&nbsp;</p><p><u>Very rare side effects (may affect up to 1 in 10,000 people):</u></p><p>Progressive scarring of lung tissue (interstitial lung disease)**.</p><p><u>Not known </u></p><p>Intestinal angioedema: a swelling in the gut presenting with symptoms like abdominal pain, nausea, vomiting, and diarrhoea has been reported after the use of similar products.</p><p>* The event may have happened by chance or could be related to a mechanism currently not known.</p><p>** Cases of progressive scarring of lung tissue have been reported during intake of telmisartan. However, it is not known whether telmisartan was the cause.</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Store below 30&deg;C. Store in the original package in order to protect from moisture. Remove your Micardis tablet from the blister only directly prior to intake.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is telmisartan.</p><p>Each tablet of Micardis 40 mg contains 40 mg telmisartan.</p><p>The other ingredients are povidone (K25), meglumine, sodium hydroxide, sorbitol (E420) and magnesium stearate.</p><p>Each tablet of Micardis 80 mg contains 80 mg telmisartan.</p><p>The other ingredients are povidone (K25), meglumine, sodium hydroxide, sorbitol (E420) and magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Micardis 40 mg tablets are white, oblong-shaped, and engraved with the code number '51H' on one side and the company logo on the other side. 
Micardis 80 mg tablets are white, oblong-shaped and engraved with the code number '52H' on one side and the company logo on the other side. 

Micardis is available in blister packs containing 14 (7x2), 28 (7x4), 56 (7x8), 84 (7x12), or 98 (7x14) tablets, in unit dose blister packs containing 28 (7x4), 30 (3 x 10) or 90 (9 x 10) tablets or in multipacks containing 360 (4 packs of 90 (9 x 10)) tablets. 

Not all strengths and pack sizes are registered or marketed in your country.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder </strong></p><p>Boehringer Ingelheim International GmbH</p><p>Binger Strasse 173</p><p>55216 Ingelheim am Rhein Germany</p><p><strong>&nbsp;</strong></p><p><strong>Bulk Manufacturer </strong></p><p>Rottendorf Pharma GmbH</p><p>Ostenfelder Stra&szlig;e 51- 61</p><p>59320 Ennigerloh</p><p>Germany</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in December 2024

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي عقار ميكارديس إلى مجموعة من الأدوية تعرف باسم مضادات مستقبلات الأنجيوتنسين-2. يُعد أنجيوتنسين-2 إحدى المواد التي يتم إفرازها في جسمك التي تتسبب في تضيُّق أوعيتك الدموية؛ مما يؤدي إلى ارتفاع ضغط دمك. يحصر عقار ميكارديس تأثير أنجيوتنسين-2، مؤديًا إلى توسُّع الأوعية الدَّموية وبالتَّالي انخفاض ضغط الدَّم لديك.</p><p dir="RTL"><strong>ستخدَم عقار ميكارديس</strong> لعلاج البالغين من ارتفاع ضغط الدَّم الأساسي. يُقصد بكلمة &quot;الأساسي&quot; أن ارتفاع ضغط الدَّم غير ناجم عن أية حالة أخرى.</p><p dir="RTL">قد يتسبب ارتفاع ضغط الدَّم، إذا لم يُعالج، في إتلاف الأوعية الدموية بالعديد من الأعضاء؛ مما قد يؤدي أحيانًا إلى الإصابة بنوبة قلبية، أو فشل في القلب أو الكُلى، أو سكتة دماغية، أو فقدان البصر. لا تُوجد عادةً أي أعراض تشير إلى ارتفاع ضغط الدَّم قبل حدوث الضرر. لذلك فمن المهم قياس ضغط الدَّم بشكل منتظم للتحقُّق من كونه ضمن النطاق الطبيعي.</p><p dir="RTL"><strong>يُستَخدَم عقار ميكارديس أيضًا </strong>للحد من أحداث القلب والأوعية الدَّموية (أي النوبة القلبية أو السكتة الدماغية) في البالغين المُعرضين للخطر نتيجة انخفاض أو انسداد إمداد القلب أو الساقين بالدَّم أو إصابتهم بسكتة دماغية أو كونهم عُرضة بشكل كبير لخطر الإصابة بمرض السُّكَّرِي. بإمكان طبيبك إخبارك بما إذا كنت مُعرضًا بشكل كبير لخطر الإصابة بتلك الأحداث أم لا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تتناول عقار ميكارديس في الحالات الآتية:</strong></p><ul><li><p>إذا كنت تعاني من حساسية تجاه تلميسارتان أو تجاه أي مكون من المكونات الأخرى بهذا الدَّواء (المدرجة في قسم 6).&nbsp;</p></li></ul><ul><li><p>إذا تجاوز حملك الشهر الثالث. (من الأفضل أيضًا تجنُّب تناوُل عقار ميكارديس في مراحل الحمل المبكرة - انظري قسم الحمل).&nbsp;</p></li></ul><ul><li><p>إذا كنت تعاني من مشاكل شديدة بالكبد مثل الركود الصفراوي أو انسداد القنوات الصفراوية (مشاكل في تفريغ العصارة الصفراوية من الكبد والمرارة) أو من مرضٍ آخر شديد بالكبد.&nbsp;</p></li></ul><ul><li><p>إذا كنت مصابًا بمرض السُّكَّري أو تُعاني من قصور بوظائف الكُلى ويتم علاجك بدواء خافض لضغط الدَّم يحتوي على أليسكيرين.&nbsp;</p></li></ul><p dir="RTL">إذا انطبق عليك أيٌّ مما ذُكر أعلاه، فأخبر طبيبك أو الصيدلي الخاص بك قبل تناوُل عقار ميكارديس.</p><p><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">تحدَّث إلى طبيبك قبل تناول عقار ميكارديس إذا كنت تعاني أو قد عانيت مسبقًا من أيٍّ من الحالات أو الأمراض التالية:</p><ul><li><p>مرض بالكُلى أو زرع الكُلى.&nbsp;</p></li></ul><ul><li><p>ضِيق الشريان الكُلوي (تضيُّق الأوعية الدموية التي تُغذِّي إحدى الكُليتين أو كليهما).&nbsp;</p></li></ul><ul><li><p>مرض بالكبد.&nbsp;</p></li></ul><ul><li><p>مشكلة بالقلب.&nbsp;</p></li></ul><ul><li><p>ارتفاع مستويات الألدوستيرون (احتفاظ الجسم بالماء والأملاح بالإضافة إلى اختلال توازن العديد من المعادن بالدم).&nbsp;</p></li></ul><ul><li><p>انخفاض ضغط الدَّم، الذي من المُرجح حدوثه إذا كنت مُصابًا بالجفاف (فقدان بالغ لكمية الماء بالجسم) أو إذا كنت تعاني من نقص بالملح نتيجة العلاج بمدرات البول (أقراص الماء) على سبيل المثال ، اتباع النظام الغذائي منخفض الملح، الإِسْهال أو القيء.&nbsp;</p></li></ul><ul><li><p>ارتفاع مستويات البوتاسيوم في دمك.&nbsp;</p></li></ul><ul><li><p>مرض السُّكَّرِي.&nbsp;</p></li></ul><p dir="RTL">تحدَّث إلى طبيبك قبل تناول عقار ميكارديس في الحالات الآتية:</p><ul><li><p>إذا كنت تتناول أيًّا من الأدوية التَّالية التي تُستَخدَم لعلاج ارتفاع ضغط الدَّم:&nbsp;</p></li></ul><ul><li><p>أحد مثبطات الأنْزيم المُحَوِّل للأَنْجيُوتَنْسين (على سبيل المثال: إنالابريل، ليزينوبريل، راميبريل)، بالأخص إذا كنت تُعاني من مشاكل بالكُلى متعلقة بمرض السُّكَّري.&nbsp;</p></li></ul><ul><li><p>أليسكيرين.&nbsp;</p></li></ul><p>قد يُجري لك طبيبك فحصًا لوظائف الكُلى وضغط الدَّم وكمية الكهارل (على سبيل المثال: البوتاسيوم) في دمك على فترات منتظمة. انظر أيضًا المعلومات تحت عنوان &quot;لا تتناول عقار ميكارديس&quot;.&nbsp;</p><ul><li><p>إذا كنت تتناول ديجوكسِين.&nbsp;</p></li></ul><p dir="RTL">تحدث إلى طبيبك إذا أُصبت بألم في البطن أو غثيان أو قيء أو إسهال بعد تناول عقار ميكارديس. سيحدد طبيبك ما ستتلقاه من علاجٍ بعدها. لا تتوقف عن تناول عقار ميكارديس من تلقاء نفسك.&nbsp;</p><p dir="RTL">يجب عليكِ إخبار طبيبكِ إذا كنتِ تعتقدين أنكِ حامل (أو قد تصبحين حاملًا). لا يُوصى بتناوُل عقار ميكارديس في مراحل الحمل المبكرة، ويجب عدم تناوُله إذا تجاوز حملكِ الشهر الثَّالث، إذ قد يُلْحِق بطفلكِ ضررًا خطيرًا إذا تم استخدامه في هذه المرحلة (انظري قسم الحمل).&nbsp;</p><p>في حال كنت ستخضع لعملية جراحية أو كنت ستتلقى أدوية تخدير، ينبغي عليك إخبار طبيبك بأنك تتناول عقار ميكارديس. قد تقل فعالية عقار ميكارديس في خفض ضغط الدَّم لدى المرضى من أصحاب البشرة السمراء.&nbsp;</p><p><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا يُوصى باستخدام عقار ميكارديس في الأطفال والمراهقين الأقل من 18 عامًا.</p><p><strong>تناوُل أدوية أخرى مع عقار ميكارديس</strong></p><p dir="RTL">يُرجى إبلاغ طبيبك أو الصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيَّة أدوية أخرى. قد يحتاج طبيبك إلى تغيير جرعة هذه الأدوية الأخرى أو اتخاذ احتياطات أخرى. قد يتعين عليك في بعض الحالات وقف تناوُل أحد الأدوية. ينطبق ذلك بوجه خاص على الأدوية المُدرجة أدناه التي يتم تناولها بالتزامن مع عقار ميكارديس:</p><ul><li><p>الأدوية التي تحتوي على الليثيوم، التي تُستَخدَم لعلاج بعض أنواع الاكتئاب.&nbsp;</p></li></ul><ul><li><p>الأدوية التي قد تزيد مستويات البوتاسيوم بالدَّم مثل بدائل الملح التي تحتوي على البوتاسيوم، ومدرات البول المُوفرة للبوتاسيوم (بعض &quot;أقراص الماء&quot;)، ومُثبطات أنزيم تحويل الأنجيوتنسين، و مضادات مستقبلات الأنجيوتنسين -2، ومضادات الالتهاب غير الستيرويدية (على سبيل المثال: الأسبرين أو إيبوبروفين)، وهيبارين، ومثبطات المناعة (على سبيل المثال: سيكلوسبورين أو تاكروليموس)، والمضاد الحيوي ترايميثوبريم.&nbsp;</p></li></ul><ul><li><p>قد تتسبب مُدِرات البول (&quot;أقراص الماء&quot;)، خاصةً إذا تم تناوُلها بجرعات مرتفعة بمصاحبة عقار ميكارديس، في فقدان بالغ لمياه الجسم وانخفاض ضغط الدَّم.&nbsp;</p></li></ul><ul><li><p>إذا كنت تتناول مثبط الأنْزيم المُحَوِّل للأَنْجيُوتَنْسين أو أليسكيرين (انظر أيضًا المعلومات الواردة تحت العنوانين &quot;لا تتناول عقار ميكارديس&quot; و&quot;تحذيرات واحتياطات&quot;).&nbsp;</p></li></ul><ul><li><p>ديجوكسين.&nbsp;</p></li></ul><p dir="RTL">قد ينخفض تأثير عقار ميكارديس عند تناولك لمضادات الالتهاب غير الستيرويدية (على سبيل المثال: الأسبرين أو إيبوبروفين) أو الكورتيكوستيرويدات.&nbsp;</p><p>قد يزيد عقار ميكارديس من التأثير الخافض لضغط الدَّم الخاص بالأدوية الأخرى المُستخدمة في علاج ارتفاع ضغط الدَّم أو الخاص بالأدوية التي من المُحتمل أن تخفض ضغط الدَّم (على سبيل المثال: باكلوفين، أميفوستين).&nbsp;</p><p>علاوة على ذلك، قد يتفاقم انخفاض ضغط الدَّم بشرب الكحوليات أو تناول الباربيتورات أو الأدوية المُخدِّرة أو مضادات الاكتئاب. قد يتجلى ذلك في هيئة إصابتك بدوخة عند النهوض. ينبغي عليك استشارة طبيبك إذا كنت بحاجة إلى ضبط الجرعة الخاصة بدوائك الآخر الذي تتناوله بالتَّزامن مع عقار ميكارديس.</p><p><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL"><u>الحمل</u></p><p dir="RTL">يجب عليكِ إخبار طبيبكِ إذا كنتِ تعتقدين أنكِ حامل (أو قد تصبحين حاملًا). سينصحكِ طبيبكِ عادةً بالتَّوقُّف عن تناوُل عقار ميكارديس قبل أن تُصبِحي حاملًا، أَو بِمجرّد أَن تعلمي أنكِ حامل، وسينصحكِ بِتناوُل دواء آخر بدلًا من عقار ميكارديس. لا يُوصى باستخدام عقار ميكارديس في مراحل الحمل المبكرة، ويجب ألا يتم تناوُله إذا تجاوز حملكِ الشهر الثالث؛ حيث إنه قد يُسبب أضرارًا خطيرة لطفلك إذا تم استخدامه بعد الشهر الثالث من الحمل.&nbsp;</p><p dir="RTL"><u>الرضاعة الطبيعية</u></p><p dir="RTL">أخبري طبيبك إذا كنتِ تُرضعين طفلكِ طبيعيًّا، أو على وشك البدء في إرضاعه طبيعيًّا. لا يُوصى باستخدام عقار ميكارديس من قِبَل الأمهات اللاتي يمارسن الرضاعة الطبيعية، وقد يختار لكِ طبيبك علاجًا آخر إذا كنتِ ترغبين في الإرضاع، خاصةً إذا كان طفلكِ حديث الولادة، أو مبتسرًا.&nbsp;</p><p><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يعاني بعض الأشخاص من آثار جانبية مثل الإغماء أو الشعور بالدوران (الدوار) عند تناول دواء ميكارديس.</p><p dir="RTL">إذا شعرت بهذه الآثار الجانبية، فلا تقود أو تشغل أي آلات.</p><p dir="RTL">&nbsp;</p><p><strong>يحتوي عقار ميكارديس على السوربيتول.</strong></p><p dir="RTL">يحتوي عقار ميكارديس البالغ 40 مجم على 168.64 مجم من السوربيتول بكل قرص.</p><p dir="RTL">يحتوي عقار ميكارديس البالغ 80 مجم على 337.28 مجم من السوربيتول بكل قرص. السوربيتول هو أحد مصادر الفركتوز. إذا أخبرك طبيبك بأنك لا تتحمل بعض أنواع السكريات أو إذا كنت شُخِّصْت بعدم تحمُّل الفركتوز الوراثي، وهو اضطراب جيني نادر يعجز الشخص بسببه عن حَلّ الفركتوز، فتحدَّث إلى طبيبك قبل تناوُل أو تلقي هذا الدَّواء.&nbsp;</p><p><strong>يحتوي عقار ميكارديس على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدَّواء على أقل من 1 مللي مول من الصوديوم (23 مجم) بكل قرص، أي إنه &quot;خالٍ من الصوديوم&quot; بشكل أساسي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول دائمًا هذا الدَّواء كما أخبرك طبيبك بالضبط. راجع طبيبك أو الصيدلي الخاص بك إذا لم تكن متأكدًا من كيفية الاستخدام.</p><p dir="RTL">الجُرعة المُوصى بها هي قرص واحد في اليوم. حاول تناول القرص في الوقت نفسه من كل يوم.</p><p dir="RTL">يمكنك تناول عقار ميكارديس مع الطعام أو بدونه. ينبغي ابتلاع الأقراص بالكامل مع بعض الماء أو غيره من المشروبات غير الكحولية. من المهم أن تستمر في تناول عقار ميكارديس يوميًّا حتى يخبرك طبيبك بخلاف ذلك. إذا شعرت أن تأثير عقار ميكارديس أقوى من اللازم أو أقل من اللازم، فاتصل بطبيبك أو بالصيدلي.&nbsp;</p><p dir="RTL">لعلاج ارتفاع ضغط الدَّم، تبلغ الجرعة المُعتادة من عقار ميكارديس بالنسبة لمعظم المرضى قرصًا واحدًا يبلغ 40 مجم مرة واحدة يوميًّا للتحكم بضغط الدَّم على مدار مدة تبلغ 24 ساعة. مع ذلك، فقد يوصي طبيبك بجرعة أقل تبلغ 20 مجم أو جرعة أعلى تبلغ 80 مجم. بدلًا من ذلك، يمكن استخدام عقار ميكارديس بمصاحبة مُدِرات البول (&quot;أقراص الماء&quot;) مثل هيدروكلوروثيازيد الذي ثبت أن له تأثيرًا إضافيًّا خافضًا لضغط الدَّم عند استخدامه بمصاحبة عقار ميكارديس.&nbsp;</p><p dir="RTL">للحد من أحداث القلب والأوعية الدَّموية، تبلغ الجرعة المُعتادة من عقار ميكارديس قرصًا واحدًا يبلغ 80 مجم مرة واحدة يوميًّا. عند بدء العلاج الوقائي بعقار ميكارديس البالغ 80 مجم، ينبغي مراقبة ضغط الدَّم بصفة منتظمة.&nbsp;</p><p dir="RTL">إذا لم يكن كبدك يعمل كما يجب، ينبغي ألا تتجاوز الجرعة المعتادة 40 مجم مرة واحدة يوميًّا.&nbsp;</p><p><strong>إذا تناولت كمية أكثر مما يجب من عقار ميكارديس</strong></p><p dir="RTL">إذا تناولت كمية أكبر من اللازم من الأقراص بطريق الخطأ، فاتصل بطبيبك أو الصيدلي الخاص بك أو قسم الطَّوارئ بأقرب مستشفى على الفور.</p><p><strong>إذا أغفلت تناوُل عقار ميكارديس</strong></p><p dir="RTL">لا داعي للقلق إذا أغفلت تناوُل إحدى الجرعات. قم بتناولها بمجرد تذكُّرك لها، ثم أكمل كالمعتاد. إذا لم تتناول القرص الخاص بك في أحد الأيام، فتناول جرعتك المعتادة في اليوم التالي. <strong><em>لا</em> </strong>تتناول جرعة مضاعفة لتعويض جرعات مفردة نسيتها.</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية عن استخدام هذا الدَّواء، فاستشر طبيبك أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء آثارًا جانبية، على الرغم من عدم حدوثها لدى الجميع.</p><p><strong>بعض الآثار الجانبية قد تكون خطيرة، وتحتاج إلى عناية طبية فورية:</strong></p><p dir="RTL">عليك رؤية طبيبك فورًا إذا تعرضت لأي من الأعراض التالية:</p><p dir="RTL">يُعد تعفن الدم* (غالبًا ما يُدعى &quot;تسمم الدم&quot;، عدوى خطيرة مصحوبة باستجابة التهابية للجسم بأكمله)، وتورم الجلد والغشاء المخاطي (وذمة وعائية) بشكل سريع؛ تُعد هذه الآثار الجانبية نادرة (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 1000 شخص) إلا أنها شديدة الخطورة، وينبغي على المرضى التَّوقف عن تناول الدَّواء ورؤية طبيبهم على الفور. قد تؤدي هذه الآثار إلى الوفاة إذا لم تُعالج.</p><p><strong>الآثار الجانبية المُحتَمَلة لعقار ميكارديس</strong></p><p dir="RTL"><u>الآثار الجانبية الشَّائعة</u> (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10&nbsp;أشخاص):</p><p dir="RTL">انخفاض ضغط الدَّم في المُستَخدِمين الذين خضعوا للعلاج بالعقار للحد من أحداث القلب والأوعية الدَّموية.&nbsp;</p><p dir="RTL"><u>الآثار الجانبية غير الشائعة</u> (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 100 شخص):</p><p dir="RTL">عدوى بالمسالك البولية، وعدوى بالجهاز التَّنفسي العلوي (على سبيل المثال: التهاب الحلق، التهاب الجيوب الأنفية، نزلة برد)، نقص في خلايا الدَّم الحمراء (فقر الدَّم)، ارتفاع مستويات البوتاسيوم، صعوبة النوم، الشعور بالحزن (اكتئاب)، إغماء (غشي)، شعور بالدوران (دوار)، تباطؤ معدل ضربات القلب، انخفاض ضغط الدَّم في المُستَخدِمين المُعَالَجين من ارتفاع ضغط الدَّم، دوخة عند النهوض (انخفاض ضغط الدَّم الانتصابي)، ضيق النفس، سعال، ألم بالبطن، إسهال، انتفاخ، قيء، حكة، زيادة التعرُّق، طفح جلدي دوائي، ألم بالظهر، تقلصات عضلية، ألم بالعضلات (ألم عضلي)، قصور بوظائف الكُلى يشمل الفشل الكُلوي الحاد، ألم بالصدر، الشعور بالضعف، ارتفاع مستويات الكرياتينين بالدَّم.&nbsp;</p><p dir="RTL"><u>الآثار الجانبية النادرة</u> (قد تؤثر على ما يصل إلى شخص واحد من بين كل 1000 شخص):</p><p dir="RTL">تعفن الدَّم* (الذي يُطلق عليه عادة &quot;تسمم الدَّم&quot; هو عدوى شديدة مصحوبة باستجابة التهابية للجسم بأكمله قد تؤدي للوفاة)، ارتفاع بعض خلايا الدَّم البيضاء (كثرة خلايا اليُوزينِيَّات)، انخفاض تعداد الصَّفائح الدَّموية (نقص الصَّفائح الدَّموية)، تفاعل حساسية شديد (تفاعل تَأَقي)، تفاعل حساسية (على سبيل المثال: طفح جلدي، حكة، صعوبة بالتَّنفس، أزيز بالصدر، تورُّم الوجه أو انخفاض ضغط الدَّم)، انخفاض مستويات السكر بالدَّم (في المرضى المُصابين بمرض السُّكَّرِي)، الشعور بالقلق، نيمومة، ضعف الرؤية، تسارع ضربات القلب، جفاف الفم،شعور بعدم الراحة في منطقة البطن،تهيُّج المعدة، اضطراب بحاسة التذوق، وظائف كبد غير طبيعية (المرضى اليابانيون أكثر عُرضة للإصابة بهذا الأثر الجانبي)، تورُّم الجلد والأغشية المخاطية على نحو سريع ما قد يؤدي أيضًا للوفاة (وذمة وعائية تشمل مضاعفات خطيرة)، أكزيما (اضطراب جلدي)، احمرار الجلد، شرى (أرتكاريا)، طفح جلدي دوائي شديد، ألم بالمفاصل، ألم بالأطراف، ألم بالأوتار، مرض شبيه بنزلة البرد، انخفاض الهيموجلوبين (بروتين بالدَّم)، ارتفاع مستويات حمض اليوريك، ارتفاع أنزيمات الكبد أو فسْفُوكيناز الكرياتين بالدَّم،&nbsp; انخفاض مستويات الصوديوم .&nbsp;<u>&nbsp;</u></p><p dir="RTL"><u>الآثار الجانبية النادرة جدًّا (قد تؤثر على ما يصل إلى شخص واحد من بين كل 10000 شخص):</u></p><p dir="RTL">التندُّب المُترقي لأنسجة الرئة (مرض الرئة الخلالي)**</p><p dir="RTL"><u>غير معروفة&nbsp;</u></p><p dir="RTL">وذمة وعائية معوية: تم الإبلاغ عن حدوث تورم في الأمعاء تظهر معه أعراض مثل ألم بالبطن وغثيان وقيء وإسهال بعد استخدام منتجات مماثلة.&nbsp;</p><p dir="RTL">* قد يكون الحدث قد وقع بمحض الصدفة، أو قد يكون مرتبطًا بآلية غير معروفة حاليًّا.</p><p dir="RTL">**تم الإبلاغ عن حالات من التندُّب المُترقي لأنسجة الرئة أثناء تناول تلميسارتان. مع ذلك، من غير المعروف ما إذا كان تلميسارتان هو السبب في ذلك.</p><p dir="RTL">&nbsp;</p><p><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا ظهرت لديك أية آثار جانبية، فتحدَّث إلى الطبيب أو الصيدلي الخاص بك. ويشمل ذلك أية آثار جانبية مُحتمَلة، غير المُدرجة في هذه النَّشرة. بإبلاغك عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات عن أمان استخدام هذا الدَّواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</p><p dir="RTL">لا تستخدم هذا الدَّواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الكرتونيَّة بعد الكلمة &ldquo;EXP&rdquo;. يُشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">يُحفَظ في درجة حرارة أقل من 30 درجة مئوية. يجب التَّخزين داخل العبوة الأصلية للحماية من الرطوبة. لا تُخرج قرص عقار ميكارديس من الشريط إلا قبل تناوله مباشرة.</p><p dir="RTL">لا تتخلص من الأدوية عن طريق إلقائها في مياه الصَّرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تَعُد تستخدمها. ستساعد هذه الإجراءات في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي تلميسارتان.</p><p dir="RTL">يحتوي كل قرص من عقار ميكارديس البالغ 40 مجم على 40 مجم من تلميسارتان.</p><p dir="RTL">المكونات الأخرى هي بوفيدون (25K)، وميجلومين، وهيدروكسيد الصوديوم، وسوربيتول (420E) وستيرات الماغنيسيوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي كل قرص من عقار ميكارديس البالغ 80 مجم على 80 مجم من تلميسارتان.</p><p dir="RTL">المكونات الأخرى هي بوفيدون (25K)، وميجلومين، وهيدروكسيد الصوديوم، وسوربيتول (420E) وستيرات الماغنسيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أقراص عقار ميكارديس البالغة 40 مجم هي عبارة عن أقراص مستطيلة الشكل وبيضاء اللون، محفور على أحد جانبيها الرقم الرمزي &quot;H51&quot; وشعار الشركة على الجانب الآخر.</p><p dir="RTL">أقراص عقار ميكارديس البالغة 80 مجم هي عبارة عن أقراص مستطيلة الشكل وبيضاء اللون، محفور على أحد جانبيها الرقم الرمزي &quot;H52&quot; وشعار الشركة على الجانب الآخر.</p><p dir="RTL">يتوافر عقار ميكارديس في عبوات بها شرائط تحتوي على 14(2&times;7) قرصًا أو 28(4&times;7) قرصًا أو 56(7&times;8) قرصًا أو 84(7&times;12) قرصًا أو 98(7&times;14) قرصًا، في عبوات بها شرائط الجرعة المفردة التي تحتوي على 28(4&times;7) قرصًا أو 30(3&times;10) قرصًا أو 90(9&times;10) قرصًا أو في عبوات متعددة تحتوي على 360 (4 عبوات بها 90 (10&times;9 )) قرصًا.</p><p dir="RTL">قد لا تكون جمیع التركیزات و أحجام العبوات مسجلة أو مسوقة ببلدك.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك حق التسويق </strong></p><p dir="RTL">شركة بوهرينجر إنجيلهايم إنترناشونال المحدودة</p><p dir="RTL">173 شارع بنجر</p><p>55216 إنجلهايم أيه إم راين</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>جهة التصنيع</strong></p><p dir="RTL">شركة روتيندورف فارما المحدودة</p><p dir="RTL">51- 61 شارع أوستنفيلدر</p><p dir="RTL">59320 إنيجرلوه</p><p dir="RTL">ألمانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة لهذه النشرة في  ديسيمبر 2024
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Micardis 20 mg tablets
Micardis 40 mg tablets
Micardis 80 mg tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Micardis 20 mg tablets 
Each tablet contains 20 mg telmisartan. 
 
Micardis 40 mg tablets 
Each tablet contains 40 mg telmisartan. 
 
Micardis 80 mg tablets 
Each tablet contains 80 mg telmisartan. 

Excipients with known effect 
Each 20 mg tablet contains 84 mg sorbitol (E420). 
Each 40 mg tablet contains 169 mg sorbitol (E420). 
Each 80 mg tablet contains 338 mg sorbitol (E420). 

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet 
Micardis 20 mg tablets 
White round tablets of 2.5 mm engraved with the code number ‘50H’ on one side and the company logo on the other side. 

Micardis 40 mg tablets 
White oblong tablets of 3.8 mm engraved with the code number ‘51H’ on one side and the company logo on the other side. 

Micardis 80 mg tablets 
White oblong tablets of 4.6 mm engraved with the code number ‘52H’ on one side and the company logo on the other side. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hypertension&nbsp;</p><p>Treatment of essential hypertension in adults.&nbsp;</p><p>Cardiovascular prevention&nbsp;</p><p>Reduction of cardiovascular morbidity in adults with:&nbsp;</p><ul><li><p>manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or&nbsp;</p></li></ul><ul><li><p>type 2 diabetes mellitus with documented target organ damage&nbsp;</p></li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology&nbsp;</p><p>Treatment of essential hypertension&nbsp;</p><p>The usually effective dose is 40 mg once daily. Some patients may already benefit at a daily dose of 20 mg. In cases where the target blood pressure is not achieved, the dose of telmisartan can be increased to a maximum of 80 mg once daily. When considering raising the dose, it must be borne in mind that the maximum antihypertensive effect is generally attained 4 to 8 weeks after the start of treatment (see section 5.1). Alternatively, telmisartan may be used in combination with thiazide-type diuretics such as hydrochlorothiazide, which has been shown to have an additive blood pressure lowering effect with telmisartan.&nbsp;&nbsp;</p><p>Cardiovascular prevention&nbsp;</p><p>The recommended dose is 80 mg once daily. It is not known whether doses lower than 80 mg of telmisartan are effective in reducing cardiovascular morbidity.&nbsp;</p><p>When initiating telmisartan therapy for the reduction of cardiovascular morbidity, close monitoring of blood pressure is recommended, and if appropriate adjustment of medications that lower blood pressure may be necessary.&nbsp;</p><p>Elderly&nbsp;</p><p>No dose adjustment is necessary for elderly patients.&nbsp;</p><p>Renal impairment&nbsp;</p><p>Limited experience is available in patients with severe renal impairment or haemodialysis. A lower starting dose of 20 mg is recommended in these patients (see section 4.4). No posology adjustment is required for patients with mild to moderate renal impairment. Telmisartan is not removed from blood by hemofiltration and is not dialyzable.&nbsp;</p><p>Hepatic impairment&nbsp;</p><p>Micardis is contraindicated in patients with severe hepatic impairment (see section 4.3).&nbsp;</p><p>In patients with mild to moderate hepatic impairment, the posology should not exceed 40 mg once daily (see section 4.4).&nbsp;</p><p>Paediatric population&nbsp;</p><p>The safety and efficacy of Micardis in children and adolescents aged below 18 years have not been established.&nbsp;</p><p>Currently available data are described in section 5.1 and 5.2 but no recommendation on a posology can be made.&nbsp;</p><p>Method of administration&nbsp;</p><p>Telmisartan tablets are for once-daily oral administration and should be swallowed whole with liquid, with or without food.&nbsp;</p><p>Precautions to be taken before handling or administering the medicinal product.&nbsp;</p><p>Telmisartan should be kept in the sealed blister due to the hygroscopic property of the tablets. Tablets should be taken out of the blister shortly before administration (see section 6.6).&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 
Second and third trimesters of pregnancy (see sections 4.4 and 4.6) 
Biliary obstructive disorders 
Severe hepatic impairment 
The concomitant use of Micardis with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 mL/min/1.73 m2) (see sections 4.5 and 5.1).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy&nbsp;</p><p>Angiotensin II receptor blockers should not be initiated during pregnancy. Unless continued angiotensin II receptor blocker therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with angiotensin II receptor blockers should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).&nbsp;</p><p>Hepatic impairment&nbsp;</p><p>Micardis is not to be given to patients with cholestasis, biliary obstructive disorders or severe hepatic impairment (see section 4.3) since telmisartan is mostly eliminated with the bile. These patients can be expected to have reduced hepatic clearance for telmisartan. Micardis should be used only with caution in patients with mild to moderate hepatic impairment.&nbsp;</p><p>Renovascular hypertension&nbsp;</p><p>There is an increased risk of severe hypotension and renal insufficiency when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated with medicinal products that affect the renin-angiotensin-aldosterone system.&nbsp;</p><p>Renal impairment and kidney transplantation&nbsp;</p><p>When Micardis is used in patients with impaired renal function, periodic monitoring of potassium and creatinine serum levels is recommended. There is no experience regarding the administration of Micardis in patients with recent kidney transplantation.&nbsp;</p><p>Telmisartan is not removed from blood by haemofiltration and is not dialyzable.&nbsp;</p><p>Volume- and/or sodium-depleted patients&nbsp;</p><p>Symptomatic hypotension, especially after the first dose of Micardis, may occur in patients who are volume- and/or sodium-depleted by e.g. vigorous diuretic therapy, dietary salt restriction, diarrhoea, or vomiting. Such conditions should be corrected before the administration of Micardis. Volume and/or sodium depletion should be corrected prior to administration of Micardis.&nbsp;</p><p>Dual blockade of the renin-angiotensin-aldosterone system (RAAS)&nbsp;</p><p>There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended (see sections 4.5 and 5.1).&nbsp;</p><p>If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.&nbsp;</p><p>ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.&nbsp;</p><p>Other conditions with stimulation of the renin-angiotensin-aldosterone system&nbsp;</p><p>In patients whose vascular tone and renal function depend predominantly on the activity of the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure or underlying renal disease, including renal artery stenosis), treatment with medicinal products that affect this system such as telmisartan has been associated with acute hypotension, hyperazotaemia, oliguria, or rarely acute renal failure (see section 4.8).&nbsp;</p><p>Primary aldosteronism&nbsp;</p><p>Patients with primary aldosteronism generally will not respond to antihypertensive medicinal products acting through inhibition of the renin-angiotensin system. Therefore, the use of telmisartan is not recommended.&nbsp;</p><p>Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy&nbsp;</p><p>As with other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.&nbsp;</p><p>Diabetic patients treated with insulin or antidiabetics&nbsp;</p><p>In these patients hypoglycaemia may occur under telmisartan treatment. Therefore, in these patients an appropriate blood glucose monitoring should be considered; a dose adjustment of insulin or antidiabetics may be required, when indicated.&nbsp;</p><p>Hyperkalaemia&nbsp;</p><p>The use of medicinal products that affect the renin-angiotensin-aldosterone system may cause hyperkalaemia.&nbsp;</p><p>In the elderly, in patients with renal insufficiency, in diabetic patients, in patients concomitantly treated with other medicinal products that may increase potassium levels, and/or in patients with intercurrent events, hyperkalaemia may be fatal.&nbsp;</p><p>Before considering the concomitant use of medicinal products that affect the renin-angiotensin-aldosterone system, the benefit risk ratio should be evaluated.&nbsp;</p><p>The main risk factors for hyperkalaemia to be considered are:&nbsp;</p><p>- Diabetes mellitus, renal impairment, age (&gt; 70 years)&nbsp;</p><p>- Combination with one or more other medicinal products that affect the renin-angiotensin-aldosterone system and/or potassium supplements. Medicinal products or therapeutic classes of medicinal products that may provoke hyperkalaemia are salt substitutes containing potassium, potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor blockers, non steroidal anti-inflammatory medicinal products (NSAIDs, including selective COX2 inhibitors), heparin, immunosuppressives (cyclosporin or tacrolimus), and trimethoprim.&nbsp;</p><p>- Intercurrent events, in particular dehydratation, acute cardiac decompensation, metabolic acidosis, worsening of renal function, sudden worsening of the renal condition (e.g. infectious diseases), cellular lysis (e.g. acute limb ischemia, rhabdomyolysis, extend trauma).&nbsp;</p><p>Close monitoring of serum potassium in at risk patients is recommended (see section 4.5).&nbsp;</p><p>Ethnic differences&nbsp;</p><p>As observed for angiotensin converting enzyme inhibitors, telmisartan and the other angiotensin II receptor blockers are apparently less effective in lowering blood pressure in black people than in non-blacks, possibly because of higher prevalence of low-renin states in the black hypertensive population.&nbsp;</p><p>Ischaemic heart disease&nbsp;</p><p>As with any antihypertensive agent, excessive reduction of blood pressure in patients with ischaemic cardiopathy or ischaemic cardiovascular disease could result in a myocardial infarction or stroke.&nbsp;</p><p>Intestinal angioedema&nbsp;</p><p>Intestinal angioedema has been reported in patients treated with angiotensin II receptor antagonists (see section 4.8). These patients presented with abdominal pain, nausea, vomiting and diarrhoea. Symptoms resolved after discontinuation of angiotensin II receptor antagonists. If intestinal angioedema is diagnosed, telmisartan should be discontinued and appropriate monitoring should be initiated until complete resolution of symptoms has occurred.&nbsp;</p><p>Sorbitol&nbsp;</p><p>Micardis 20 mg tablets&nbsp;</p><p>Micardis 20 mg tablets contain 84.32 mg sorbitol in each tablet.&nbsp;</p><p>Micardis 40 mg tablets&nbsp;</p><p>Micardis 40 mg tablets contain 168.64 mg sorbitol in each tablet.&nbsp;</p><p>Micardis 80 mg tablets&nbsp;</p><p>Micardis 80 mg tablets contain 337.28 mg sorbitol in each tablet. Patients with hereditary fructose intolerance (HFI) should not take this medicinal product.&nbsp;</p><p>Sodium&nbsp;</p><p>Each tablet contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Digoxin&nbsp;</p><p>When telmisartan was co-administered with digoxin, median increases in digoxin peak plasma concentration (49%) and in trough concentration (20%) were observed. When initiating, adjusting, and discontinuing telmisartan, monitor digoxin levels in order to maintain levels within the therapeutic range.&nbsp;</p><p>As with other medicinal products acting on the renin-angiotensin-aldosterone system, telmisartan may provoke hyperkalaemia (see section 4.4). The risk may increase in case of treatment combination with other medicinal products that may also provoke hyperkalaemia (salt substitutes containing potassium, potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor blockers, non steroidal anti-inflammatory medicinal products (NSAIDs, including selective COX2 inhibitors), heparin, immunosuppressives (cyclosporin or tacrolimus), and trimethoprim).&nbsp;</p><p>The occurrence of hyperkalaemia depends on associated risk factors. The risk is increased in case of the above-mentioned treatment combinations. The risk is particularly high in combination with potassium sparing-diuretics, and when combined with salt substitutes containing potassium. A combination with ACE inhibitors or NSAIDs, for example, presents a lesser risk provided that precautions for use are strictly followed.&nbsp;</p><p>Concomitant use not recommended.&nbsp;</p><p>Potassium sparing diuretics or potassium supplements&nbsp;</p><p>Angiotensin II receptor blockers such as telmisartan, attenuate diuretic induced potassium loss. Potassium sparing diuretics e.g. spirinolactone, eplerenone, triamterene, or amiloride, potassium supplements, or potassium-containing salt substitutes may lead to a significant increase in serum potassium. If concomitant use is indicated because of documented hypokalaemia, they should be used with caution and with frequent monitoring of serum potassium.&nbsp;</p><p>Lithium&nbsp;</p><p>Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors, and with angiotensin II receptor blockers, including telmisartan. If use of the combination proves necessary, careful monitoring of serum lithium levels is recommended.&nbsp;</p><p>Concomitant use requiring caution.&nbsp;</p><p>Non-steroidal anti-inflammatory medicinal products&nbsp;</p><p>NSAIDs (i.e. acetylsalicylic acid at anti-inflammatory dosage regimens, COX2 inhibitors and non-selective NSAIDs) may reduce the antihypertensive effect of angiotensin II receptor blockers.&nbsp;</p><p>In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function), the co-administration of angiotensin II receptor blockers and agents that inhibit cyclo-oxygenase may result in further deterioration of renal function, including possible acute renal failure, which is usually reversible. Therefore, the combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring of renal function after initiation of concomitant therapy and periodically thereafter.&nbsp;</p><p>In one study the co-administration of telmisartan and ramipril led to an increase of up to 2.5 fold in the AUC024 and Cmax of ramipril and ramiprilat. The clinical relevance of this observation is not known.&nbsp;</p><p>Diuretics (thiazide or loop diuretics)&nbsp;</p><p>Prior treatment with high dose diuretics such as furosemide (loop diuretic) and hydrochlorothiazide (thiazide diuretic) may result in volume depletion, and in a risk of hypotension when initiating therapy with telmisartan.&nbsp;</p><p>To be taken into account with concomitant use.&nbsp;</p><p>Other antihypertensive agents&nbsp;</p><p>The blood pressure lowering effect of telmisartan can be increased by concomitant use of other antihypertensive medicinal products.&nbsp;</p><p>Clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone-system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).&nbsp;</p><p>Based on their pharmacological properties it can be expected that the following medicinal products may potentiate the hypotensive effects of all antihypertensives including telmisartan: Baclofen, amifostine. Furthermore, orthostatic hypotension may be aggravated by alcohol, barbiturates, narcotics, or antidepressants.&nbsp;</p><p>Corticosteroids (systemic route)&nbsp;</p><p>Reduction of the antihypertensive effect.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy&nbsp;</p><p>The use of angiotensin II receptor blockers is not recommended during the first trimester of pregnancy (see section 4.4). The use of angiotensin II receptor blockers is contraindicated during the second and third trimesters of pregnancy (see sections 4.3 and 4.4).&nbsp;</p><p>There are no adequate data from the use of Micardis in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3).&nbsp;</p><p>Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with angiotensin II receptor blockers, similar risks may exist for this class of drugs. Unless continued angiotensin II receptor blocker therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with angiotensin II receptor blockers should be stopped immediately, and, if appropriate, alternative therapy should be started.&nbsp;</p><p>Exposure to angiotensin II receptor blocker therapy during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see section 5.3).&nbsp;</p><p>Should exposure to angiotensin II receptor blockers have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.&nbsp;</p><p>Infants whose mothers have taken angiotensin II receptor blockers should be closely observed for hypotension (see sections 4.3 and 4.4).&nbsp;</p><p>Breast-feeding&nbsp;</p><p>Because no information is available regarding the use of Micardis during breast-feeding, Micardis is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.&nbsp;</p><p>Fertility&nbsp;</p><p>In preclinical studies, no effects of Micardis on male and female fertility were observed.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>When driving vehicles or operating machinery it should be taken into account that syncope or vertigo may occasionally occur when taking antihypertensive therapy such as Micardis.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile&nbsp;</p><p>Serious adverse drug reactions include anaphylactic reaction and angioedema which may occur rarely (&ge; 1/10 000 to &lt; 1/1 000), and acute renal failure.&nbsp;</p><p>The overall incidence of adverse reactions reported with telmisartan was usually comparable to placebo (41,4% vs 43.9 %) in controlled trials in patients treated for hypertension. The incidence of adverse reactions was not dose related and showed no correlation with gender, age or race of the patients. The safety profile of telmisartan in patients treated for the reduction of cardiovascular morbidity was consistent with that obtained in hypertensive patients.&nbsp;</p><p>The adverse reactions listed below have been accumulated from controlled clinical trials in patients treated for hypertension and from post-marketing reports. The listing also takes into account serious adverse reactions and adverse reactions leading to discontinuation reported in three clinical long-term studies including 21 642 patients treated with telmisartan for the reduction of cardiovascular morbidity for up to six years.&nbsp;</p><p>Tabulated list of adverse reactions&nbsp;</p><p>Adverse reactions have been ranked under headings of frequency using the following convention:&nbsp;</p><p>very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1 000 to &lt; 1/100); rare (&ge; 1/10 000 to &lt; 1/1 000); very rare (&lt; 1/10 000).&nbsp;</p><p>Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.&nbsp;</p><table border="1"><tbody><tr><td colspan="2"><p>Infections and infestations&nbsp;</p></td></tr><tr><td><p>Uncommon:&nbsp;</p></td><td><p>Urinary tract infection, cystitis, upper respiratory tract infection including pharyngitis and sinusitis&nbsp;</p></td></tr><tr><td><p>Rare:&nbsp;</p></td><td><p>Sepsis including fatal outcome1&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>Blood and lymphatic system disorders&nbsp;</p></td></tr><tr><td><p>Uncommon:&nbsp;</p></td><td><p>Anaemia&nbsp;</p></td></tr><tr><td><p>Rare:&nbsp;</p></td><td><p>Eosinophilia, thrombocytopenia&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>Immune system disorders&nbsp;</p></td></tr><tr><td><p>Rare:&nbsp;</p></td><td><p>Anaphylactic reaction, hypersensitivity&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>Metabolism and nutrition disorders&nbsp;</p></td></tr><tr><td><p>Uncommon:&nbsp;</p></td><td><p>Hyperkalaemia&nbsp;</p></td></tr><tr><td><p>Rare:&nbsp;</p></td><td><p>Hypoglycaemia (in diabetic patients), hyponatraemia&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>Psychiatric disorders&nbsp;</p></td></tr><tr><td><p>Uncommon:&nbsp;</p></td><td><p>Insomnia, depression&nbsp;</p></td></tr><tr><td><p>Rare:&nbsp;</p></td><td><p>Anxiety&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>Nervous system disorders&nbsp;</p></td></tr><tr><td><p>Uncommon:&nbsp;</p></td><td><p>Syncope&nbsp;</p></td></tr><tr><td><p>Rare:&nbsp;</p></td><td><p>Somnolence&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>Eye disorders&nbsp;</p></td></tr><tr><td><p>Rare:&nbsp;</p></td><td><p>Visual impairment&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>Ear and labyrinth disorders&nbsp;</p></td></tr><tr><td><p>Uncommon:&nbsp;</p></td><td><p>Vertigo&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>Cardiac disorders&nbsp;</p></td></tr><tr><td><p>Uncommon:&nbsp;</p></td><td><p>Bradycardia&nbsp;</p></td></tr><tr><td><p>Rare:&nbsp;</p></td><td><p>Tachycardia&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>Vascular disorders&nbsp;</p></td></tr><tr><td><p>Uncommon:&nbsp;</p></td><td><p>Hypotension2, orthostatic hypotension&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>Respiratory, thoracic and mediastinal disorders&nbsp;</p></td></tr><tr><td><p>Uncommon:&nbsp;</p></td><td><p>Dyspnoea, cough&nbsp;</p></td></tr><tr><td><p>Very rare:&nbsp;</p></td><td><p>Interstitial lung disease4&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>Gastrointestinal disorders&nbsp;</p></td></tr><tr><td><p>Uncommon:&nbsp;</p></td><td><p>Abdominal pain, diarrhoea, dyspepsia, flatulence, vomiting&nbsp;</p></td></tr><tr><td><p>Rare:&nbsp;</p></td><td><p>Dry mouth, abdominal discomfort, dysgeusia&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>Hepato-biliary disorders&nbsp;</p></td></tr><tr><td><p>Rare:&nbsp;</p></td><td><p>Hepatic function abnormal/liver disorder3&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>Skin and subcutaneous tissue disorders&nbsp;</p></td></tr><tr><td><p>Uncommon:&nbsp;</p></td><td><p>Pruritus, hyperhidrosis, rash&nbsp;</p></td></tr><tr><td><p>Rare:&nbsp;</p></td><td><p>Angioedema (including fatal outcome), eczema, erythema, urticaria, drug eruption, toxic skin eruption&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>Muscoloskeletal and connective tissue disorders&nbsp;</p></td></tr><tr><td><p>Uncommon:&nbsp;</p></td><td><p>Back pain (e.g. sciatica), muscle spasms, myalgia&nbsp;</p></td></tr><tr><td><p>Rare:&nbsp;</p></td><td><p>Arthralgia, pain in extremity, tendon pain (tendonitis like symptoms)&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>Renal and urinary disorders&nbsp;</p></td></tr><tr><td><p>Uncommon:&nbsp;</p></td><td><p>Renal impairment (including acute kidney injury)&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>General disorders and administration site conditions&nbsp;</p></td></tr><tr><td><p>Uncommon:&nbsp;</p></td><td><p>Chest pain, asthenia (weakness)&nbsp;</p></td></tr><tr><td><p>Rare:&nbsp;</p></td><td><p>Influenza-like illness&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>Investigations&nbsp;</p></td></tr><tr><td><p>Uncommon:&nbsp;</p></td><td><p>Blood creatinine increased&nbsp;</p></td></tr><tr><td><p>Rare:&nbsp;</p></td><td><p>Haemoglobin decreased, blood uric acid increased, hepatic enzyme increased, blood creatine phosphokinase increased&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table><p>1,2,3,4: for further description, please see sub-section &ldquo;Description of selected adverse reactions&rdquo;&nbsp;</p><p>Description of selected adverse reactions&nbsp;</p><p>Sepsis&nbsp;</p><p>In the PRoFESS trial, an increased incidence of sepsis was observed with telmisartan compared with placebo. The event may be a chance finding or related to a mechanism currently not known (see also section 5.1).&nbsp;</p><p>Hypotension&nbsp;</p><p>This adverse reaction was reported as common in patients with controlled blood pressure who were treated with telmisartan for the reduction of cardiovascular morbidity on top of standard care.&nbsp;</p><p>Hepatic function abnormal / liver disorder&nbsp;</p><p>Most cases of hepatic function abnormal / liver disorder from post-marketing experience occurred in Japanese patients. Japanese patients are more likely to experience these adverse reactions.&nbsp;</p><p>Interstitial lung disease&nbsp;</p><p>Cases of interstitial lung disease have been reported from post-marketing experience in temporal association with the intake of telmisartan. However, a causal relationship has not been established.&nbsp;</p><p>Intestinal angioedema&nbsp;</p><p>Cases of intestinal angioedema have been reported after the use of angiotensin II receptor antagonists (see section 4.4).&nbsp;</p><p>Reporting of suspected adverse reactions&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is limited information available with regard to overdose in humans.&nbsp;</p><p>Symptoms&nbsp;</p><p>The most prominent manifestations of telmisartan overdose were hypotension and tachycardia; bradycardia dizziness, increase in serum creatinine, and acute renal failure have also been reported.&nbsp;</p><p>Management&nbsp;</p><p>Telmisartan is not removed by haemofiltration and is not dialyzable. The patient should be closely monitored, and the treatment should be symptomatic and supportive. Management depends on the time since ingestion and the severity of the symptoms. Suggested measures include induction of emesis and / or gastric lavage. Activated charcoal may be useful in the treatment of overdosage. Serum electrolytes and creatinine should be monitored frequently. If hypotension occurs, the patient should be placed in a supine position, with salt and volume replacement given quickly.&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Angiotensin II receptor blockers (ARBs), plain, ATC Code: C09CA07.&nbsp;</p><p>Mechanism of action&nbsp;</p><p>Telmisartan is an orally active and specific angiotensin II receptor (type AT1) blocker. Telmisartan displaces angiotensin II with very high affinity from its binding site at the AT1 receptor subtype, which is responsible for the known actions of angiotensin II. Telmisartan does not exhibit any partial agonist activity at the AT1 receptor. Telmisartan selectively binds the AT1 receptor. The binding is long-lasting. Telmisartan does not show affinity for other receptors, including AT2 and other less characterised AT receptors. The functional role of these receptors is not known, nor is the effect of their possible overstimulation by angiotensin II, whose levels are increased by telmisartan. Plasma aldosterone levels are decreased by telmisartan. Telmisartan does not inhibit human plasma renin or block ion channels. Telmisartan does not inhibit angiotensin converting enzyme (kininase II), the enzyme which also degrades bradykinin. Therefore it is not expected to potentiate bradykinin-mediated adverse effects.&nbsp;</p><p>In human, an 80 mg dose of telmisartan almost completely inhibits the angiotensin II evoked blood pressure increase. The inhibitory effect is maintained over 24 hours and still measurable up to 48 hours.&nbsp;</p><p>Clinical efficacy and safety&nbsp;</p><p>Treatment of essential hypertension&nbsp;</p><p>After the first dose of telmisartan, the antihypertensive activity gradually becomes evident within 3 hours. The maximum reduction in blood pressure is generally attained 4 to 8 weeks after the start of treatment and is sustained during long-term therapy.&nbsp;</p><p>The antihypertensive effect persists constantly over 24 hours after dosing and includes the last 4 hours before the next dose as shown by ambulatory blood pressure measurements. This is confirmed by trough to peak ratios consistently above 80 % seen after doses of 40 and 80 mg of telmisartan in placebo controlled clinical studies. There is an apparent trend to a dose relationship to a time to recovery of baseline systolic blood pressure (SBP). In this respect data concerning diastolic blood pressure (DBP) are inconsistent.&nbsp;</p><p>In patients with hypertension telmisartan reduces both systolic and diastolic blood pressure without affecting pulse rate. The contribution of the medicinal product&rsquo;s diuretic and natriuretic effect to its hypotensive activity has still to be defined. The antihypertensive efficacy of telmisartan is comparable to that of agents representative of other classes of antihypertensive medicinal products (demonstrated in clinical trials comparing telmisartan to amlodipine, atenolol, enalapril, hydrochlorothiazide, and lisinopril).&nbsp;</p><p>Upon abrupt cessation of treatment with telmisartan, blood pressure gradually returns to pre-treatment values over a period of several days without evidence of rebound hypertension.&nbsp;</p><p>The incidence of dry cough was significantly lower in patients treated with telmisartan than in those given angiotensin converting enzyme inhibitors in clinical trials directly comparing the two antihypertensive treatments.&nbsp;</p><p>Cardiovascular prevention&nbsp;</p><p>ONTARGET (ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial) compared the effects of telmisartan, ramipril and the combination of telmisartan and ramipril on cardiovascular outcomes in 25 620 patients aged 55 years or older with a history of coronary artery disease, stroke, TIA, peripheral arterial disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage (e.g. retinopathy, left ventricular hypertrophy, macro- or microalbuminuria), which is a population at risk for cardiovascular events.&nbsp;</p><p>Patients were randomized to one of the three following treatment groups: telmisartan 80 mg (n = 8 542), ramipril 10 mg (n = 8 576), or the combination of telmisartan 80 mg plus ramipril 10 mg (n = 8 502), and followed for a mean observation time of 4.5 years.&nbsp;</p><p>Telmisartan showed a similar effect to ramipril in reducing the primary composite endpoint of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for congestive heart failure. The incidence of the primary endpoint was similar in the telmisartan (16.7 %) and ramipril (16.5 %) groups. The hazard ratio for telmisartan vs. ramipril was 1.01 (97.5 % CI 0.931.10, p (non-inferiority) = 0.0019 at a margin of 1.13). The all-cause mortality rate was 11.6 % and 11.8 % among telmisartan and ramipril treated patients, respectively.&nbsp;</p><p>Telmisartan was found to be similarly effective to ramipril in the pre-specified secondary endpoint of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke [0.99 (97.5 % CI 0.901.08), p (non-inferiority) = 0.0004], the primary endpoint in the reference study HOPE (The Heart Outcomes Prevention Evaluation Study), which had investigated the effect of ramipril vs. placebo.&nbsp;</p><p>TRANSCEND randomized ACE-I intolerant patients with otherwise similar inclusion criteria as ONTARGET to telmisartan 80 mg (n = 2 954) or placebo (n = 2 972), both given on top of standard care. The mean duration of follow up was 4 years and 8 months. No statistically significant difference in the incidence of the primary composite endpoint (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for congestive heart failure) was found [15.7 % in the telmisartan and 17.0 % in the placebo groups with a hazard ratio of 0.92 (95 % CI 0.811.05, p = 0.22)]. There was evidence for a benefit of telmisartan compared to placebo in the pre-specified secondary composite endpoint of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke [0.87 (95 % CI 0.761.00, p = 0.048)]. There was no evidence for benefit on cardiovascular mortality (hazard ratio 1.03, 95 % CI 0.851.24).&nbsp;</p><p>Cough and angioedema were less frequently reported in patients treated with telmisartan than in patients treated with ramipril, whereas hypotension was more frequently reported with telmisartan.&nbsp;</p><p>Combining telmisartan with ramipril did not add further benefit over ramipril or telmisartan alone. CV mortality and all cause mortality were numerically higher with the combination. In addition, there was a significantly higher incidence of hyperkalaemia, renal failure, hypotension and syncope in the combination arm. Therefore the use of a combination of telmisartan and ramipril is not recommended in this population.&nbsp;</p><p>In the &ldquo;Prevention Regimen For Effectively avoiding Second Strokes&rdquo; (PRoFESS) trial in patients 50 years and older, who recently experienced stroke, an increased incidence of sepsis was noted for telmisartan compared with placebo, 0.70 % vs. 0.49 % [RR 1.43 (95 % confidence interval 1.002.06)]; the incidence of fatal sepsis cases was increased for patients taking telmisartan (0.33 %) vs. patients taking placebo (0.16 %) [RR 2.07 (95 % confidence interval 1.143.76)]. The observed increased occurrence rate of sepsis associated with the use of telmisartan may be either a chance finding or related to a mechanism not currently known.&nbsp;</p><p>Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker.&nbsp;</p><p>ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage. For more detailed information see above under the heading &ldquo;Cardiovascular prevention&rdquo;.&nbsp;</p><p>VA NEPHROND was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.&nbsp;</p><p>These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as compared to monotherapy was observed. Given their similar pharmacodynamic properties, these results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers.&nbsp;</p><p>ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in patients with diabetic nephropathy.&nbsp;</p><p>ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group than in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.&nbsp;</p><p>Paediatric population&nbsp;</p><p>The safety and efficacy of Micardis in children and adolescents aged below 18 years have not been established.&nbsp;</p><p>The blood pressure lowering effects of two doses of telmisartan were assessed in 76 hypertensive, largely overweight patients aged 6 to &lt; 18 years (body weight &ge; 20 kg and &le; 120 kg, mean 74.6 kg), after taking telmisartan 1 mg/kg (n = 29 treated) or 2 mg/kg (n = 31 treated) over a four-week treatment period. By inclusion the presence of secondary hypertension was not investigated. In some of the investigated patients the doses used were higher than those recommended in the treatment of hypertension in the adult population, reaching a daily dose comparable to160 mg, which was tested in adults. After adjustment for age group effects mean SBP changes from baseline (primary objective) were 14.5 (1.7) mm Hg in the telmisartan 2 mg/kg group, 9.7 (1.7) mm Hg in the telmisartan 1 mg/kg group, and 6.0 (2.4) in the placebo group. The adjusted DBP changes from baseline were 8.4 (1.5) mm Hg, 4.5 (1.6) mm Hg and 3.5 (2.1) mm Hg respectively. The change was dose dependent. The safety data from this study in patients aged 6 to &lt; 18 years appeared generally similar to that observed in adults. The safety of long term treatment of telmisartan in children and adolescents was not evaluated.&nbsp;</p><p>An increase in eosinophils reported in this patient population has not been recorded in adults. Its clinical significance and relevance is unknown.&nbsp;</p><p>These clinical data do not allow to make conclusions on the efficacy and safety of telmisartan in hypertensive paediatric population.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption&nbsp;</p><p>Absorption of telmisartan is rapid although the amount absorbed varies. The mean absolute bioavailability for telmisartan is about 50 %. When telmisartan is taken with food, the reduction in the area under the plasma concentration-time curve (AUC0&infin;) of telmisartan varies from approximately 6 % (40 mg dose) to approximately 19 % (160 mg dose). By 3 hours after administration, plasma concentrations are similar whether telmisartan is taken fasting or with food.&nbsp;</p><p>Linearity/non-linearity&nbsp;</p><p>The small reduction in AUC is not expected to cause a reduction in the therapeutic efficacy. There is no linear relationship between doses and plasma levels. Cmax and to a lesser extent AUC increase disproportionately at doses above 40 mg.&nbsp;</p><p>Distribution&nbsp;</p><p>Telmisartan is largely bound to plasma protein (&gt; 99.5 %), mainly albumin and alpha1 acid glycoprotein. The mean steady state apparent volume of distribution (Vdss) is approximately 500 L.&nbsp;</p><p>Biotransformation&nbsp;</p><p>Telmisartan is metabolised by conjugation to the glucuronide of the parent compound. No pharmacological activity has been shown for the conjugate.&nbsp;</p><p>Elimination&nbsp;</p><p>Telmisartan is characterised by biexponential decay pharmacokinetics with a terminal elimination half-life of &gt; 20 hours. The maximum plasma concentration (Cmax) and, to a smaller extent, the area under the plasma concentration-time curve (AUC), increase disproportionately with dose. There is no evidence of clinically relevant accumulation of telmisartan taken at the recommended dose. Plasma concentrations were higher in females than in males, without relevant influence on efficacy.&nbsp;</p><p>After oral (and intravenous) administration, telmisartan is nearly exclusively excreted with the faeces, mainly as unchanged compound. Cumulative urinary excretion is &lt; 1 % of dose. Total plasma clearance (Cltot) is high (approximately 1 000 mL/min) compared with hepatic blood flow (about 1 500 mL/min).&nbsp;</p><p>Paediatric population&nbsp;</p><p>The pharmacokinetics of two doses of telmisartan were assessed as a secondary objective in hypertensive patients (n = 57) aged 6 to &lt; 18 years after taking telmisartan 1 mg/kg or 2 mg/kg over a four-week treatment period. Pharmacokinetic objectives included the determination of the steady-state of telmisartan in children and adolescents, and investigation of age-related differences. Although the study was too small for a meaningful assessment of the pharmacokinetics of children under 12 years of age, the results are generally consistent with the findings in adults and confirm the non-linearity of telmisartan, particularly for Cmax.&nbsp;</p><p>Gender&nbsp;</p><p>Differences in plasma concentrations were observed, with Cmax and AUC being approximately 3 and 2fold higher, respectively, in females compared to males.&nbsp;</p><p>Elderly&nbsp;</p><p>The pharmacokinetics of telmisartan do not differ between the elderly and those younger than 65 years.&nbsp;</p><p>Renal impairment&nbsp;</p><p>In patients with mild to moderate and severe renal impairment, doubling of plasma concentrations was observed. However, lower plasma concentrations were observed in patients with renal insufficiency undergoing dialysis. Telmisartan is highly bound to plasma protein in renal-insufficient patients and cannot be removed by dialysis. The elimination half-life is not changed in patients with renal impairment.&nbsp;</p><p>Hepatic impairment&nbsp;</p><p>Pharmacokinetic studies in patients with hepatic impairment showed an increase in absolute bioavailability up to nearly 100 %. The elimination half-life is not changed in patients with hepatic impairment.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In preclinical safety studies, doses producing exposure comparable to that in the clinical therapeutic range caused reduced red cell parameters (erythrocytes, haemoglobin, haematocrit), changes in renal haemodynamics (increased blood urea nitrogen and creatinine), as well as increased serum potassium in normotensive animals. In dogs, renal tubular dilation and atrophy were observed. Gastric mucosal injury (erosion, ulcers or inflammation) also was noted in rats and dogs. These pharmacologically-mediated undesirable effects, known from preclinical studies with both angiotensin converting enzyme inhibitors and angiotensin II receptor blockers, were prevented by oral saline supplementation.&nbsp;</p><p>In both species, increased plasma renin activity and hypertrophy/hyperplasia of the renal juxtaglomerular cells were observed. These changes, also a class effect of angiotensin converting enzyme inhibitors and other angiotensin II receptor blockers, do not appear to have clinical significance.&nbsp;</p><p>No clear evidence of a teratogenic effect was observed, however at toxic dose levels of telmisartan an effect on the postnatal development of the offsprings such as lower body weight and delayed eye opening was observed.&nbsp;</p><p>There was no evidence of mutagenicity and relevant clastogenic activity in in vitro studies and no evidence of carcinogenicity in rats and mice.&nbsp;</p><p>No effects of telmisartan on male or female fertility were observed.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Povidone (K25)</p><p>Meglumine</p><p>Sodium hydroxide</p><p>Sorbitol (E420)</p><p>Magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4 years
Do not use this medicine after the expiry date which is stated on the carton after “EXP”. The expiry date refers to the last day of that month.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>Store in the original package in order to protect from moisture.</p><p>Remove your Micardis tablet from the blister only directly prior to intake.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminium/aluminium blisters (PA/Al/PVC/Al or PA/PA/Al/PVC/Al). One blister contains 7 or 10 tablets.</p><p><u>Micardis 20 mg tablets</u></p><p>Pack sizes: Blister with 14, 28, 56 or 98 tablets.</p><p><u>Micardis 40 mg and 80 mg tablets</u></p><p>Pack sizes: Blister with 14, 28, 56, 84 or 98 tablets or perforated unit dose blisters with 28 &times; 1, 30 &times; 1 or 90 &times; 1 tablets; multipacks containing 360 (4 packs of 90 &times; 1) tablets</p><p>Not all strengths and pack sizes are registered or marketed in your country.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Telmisartan should be kept in the sealed blister due to the hygroscopic property of the tablets. Tablets should be taken out of the blister shortly before administration.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Boehringer Ingelheim International GmbH Binger Str. 173
55216 Ingelheim am Rhein Germany
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                December 2024
 

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>